Validity of Quality of Life Measurement Tools - From Generic to Disease-specific

被引:55
作者
Wells, George A. [1 ]
Russell, Anthony S.
Haraoui, Boulos
Bissonnette, Robert [2 ]
Ware, Carl F.
机构
[1] Univ Ottawa, Inst Heart, Cardiovasc Res Methods Ctr, Ottawa, ON K1Y 4W7, Canada
[2] Innovaderm Res, Montreal, PQ, Canada
关键词
HEALTH-RELATED QUALITY OF LIFE; RESPONSIVENESS; RELIABILITY; GENERIC MEASUREMENT INSTRUMENTS; DISEASE-SPECIFIC; CLINICAL-TRIALS; HEALTH-STATUS; EQ-5D; RELIABILITY; FRAMEWORK; INDEX; SF-36;
D O I
10.3899/jrheum.110906
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Health-related quality of life (HRQOL) is an important measure of a patient's perception of his/her illness. Over the past 3 decades, numerous instruments have been developed to measure HRQOL in various patient populations, with 2 basic approaches: generic and disease-specific. While generic measures have broad application across different types and severity of diseases, disease-specific measures are designed to assess particular diseases or patient populations. All HRQOL instruments, however, must be valid and have high reliability and responsiveness. Validity ensures that the instrument measures what it is supposed to measure. Reliable instruments are able to reproducibly differentiate between subjects. Responsive evaluative measures are able to detect important changes in HRQOL during a period of time, even if those changes are small. HRQOL measures should also be interpretable, meaning that the differences in scores that correspond to small, moderate, and large HRQOL changes are easily identifiable. This article describes the steps in the development of HRQOL instruments from the conceptual framework to creation and testing. Several examples of generic and disease-specific instruments commonly used to evaluate HRQOL in patients with immune-mediated inflammatory diseases (IMID) are provided. (J Rheumatol 2011;38 Suppl 88:2-6; doi:10.3899/jrheum.110906)
引用
收藏
页码:2 / 6
页数:5
相关论文
共 29 条
[1]   Cronbach's alpha [J].
Bland, JM ;
Altman, DG .
BRITISH MEDICAL JOURNAL, 1997, 314 (7080) :572-572
[2]  
Bonomi A E, 2000, J Am Pharm Assoc (Wash), V40, P402
[3]  
Cella D F, 1990, Oncology (Williston Park), V4, P29
[4]   Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease [J].
Coteur, G. ;
Feagan, B. ;
Keininger, D. L. ;
Kosinski, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (09) :1032-1041
[5]  
DeJong Z, 1997, BRIT J RHEUMATOL, V36, P878
[6]   Modeling valuations for EuroQol health states [J].
Dolan, P .
MEDICAL CARE, 1997, 35 (11) :1095-1108
[7]   Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis [J].
Doward, LC ;
Spoorenberg, A ;
Cook, SA ;
Whalley, D ;
Helliwell, PS ;
Kay, LJ ;
McKenna, SP ;
Tennant, A ;
van der Heijde, D ;
Chamberlain, MA .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (01) :20-26
[8]   The quest to quantify quality [J].
Fihn, SD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13) :1740-1742
[9]   PSORIASIS - AN INDEX OF DISABILITY [J].
FINLAY, AY ;
KELLY, SE .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1987, 12 (01) :8-11
[10]   SAMPLE-SIZE DETERMINATIONS FOR THE 2 RATER-KAPPA STATISTIC [J].
FLACK, VF ;
AFIFI, AA ;
LACHENBRUCH, PA ;
SCHOUTEN, HJA .
PSYCHOMETRIKA, 1988, 53 (03) :321-325